Parent Peptide vs Active Fragment
Thymosin Beta-4 (TB-4) is the full 43-amino acid endogenous peptide. TB-500 is a synthetic fragment of TB-4 — specifically the 7-amino acid active region (Ac-LKKTETQ, residues 17–23) responsible for actin binding and cell migration signaling.
This is one of the most frequently asked questions in peptide research. They are related but not interchangeable.
For a complete deep dive into TB-4, see our Thymosin Beta-4 Research Guide.
Mechanism Comparison
TB-4 (Full Peptide)
TB-4 is the body's primary actin-sequestering molecule. As the full-length peptide, it activates the complete native signaling cascade:
- Actin sequestration — maintains G-actin reservoir for cell migration
- Angiogenesis — upregulates VEGF for new blood vessel formation
- Anti-inflammatory — reduces IL-1β and TNF-α
- Progenitor cell activation — mobilizes epicardial and satellite stem cells
- Anti-fibrotic — reduces excessive scar tissue formation
TB-4 provides the full biological context — some downstream effects may require the complete peptide sequence.
TB-500 (Fragment)
TB-500 contains the core active region of TB-4. It retains the primary mechanism but in a smaller, more stable package:
- Actin binding — same core LKKTETQ motif that drives cell migration
- Cell migration signaling — promotes fibroblast and keratinocyte movement
- Enhanced stability — smaller molecule degrades less readily
- Superior distribution — penetrates tissues more easily due to lower molecular weight
TB-500 may lack some of TB-4's broader signaling — particularly the full progenitor cell activation cascade — but delivers the core repair signal more efficiently.
Quick Comparison Table
| Feature |
TB-4 (Thymosin Beta-4) |
TB-500 |
| Structure |
43 amino acids (full peptide) |
7 amino acids (active fragment) |
| Molecular weight |
~4,921 Da |
~843 Da |
| Origin |
Endogenous — naturally produced |
Synthetic — lab-manufactured |
| Stability |
Lower (larger molecule) |
Higher (smaller, more resistant) |
| Tissue distribution |
Broad (carried by platelets) |
Extremely broad (small molecule diffusion) |
| Core mechanism |
Complete actin + multi-pathway |
Targeted actin-binding & migration |
| Progenitor cell activation |
Yes (full cascade) |
Unclear (may be partial) |
| Anti-fibrotic |
Strong evidence |
Extrapolated from TB-4 data |
| Published research |
Extensive (Nature, PNAS, etc.) |
Limited direct studies |
| Cost |
Higher |
Lower |
| Typical dose |
2–5 mg, 2x/week |
2–5 mg, 2x/week |
Ready to buy? Compare verified vendors on our best thymosin beta-4 sources page, or browse all coupon codes for up to 50% off.
Research Applications Compared
Where TB-4 Has Stronger Evidence
- Cardiac repair — the landmark Nature studies showing epicardial progenitor cell activation used full TB-4, not TB-500
- Anti-fibrotic effects — most anti-fibrotic research uses the complete peptide
- Ocular healing — corneal wound healing trials used TB-4
- Clinical trials — Phase I human safety data exists for TB-4 specifically
Where TB-500 May Have Advantages
- Tissue penetration — 6x smaller molecule reaches more tissue
- Stability — longer shelf life, less degradation during storage
- Cost-effectiveness — lower price per equivalent dose
- Practical handling — easier reconstitution and storage
Where Both Are Studied
- Muscle repair — satellite cell activation and regeneration
- Tendon & ligament healing — fibroblast migration and collagen organization
- Wound healing — keratinocyte migration and closure
- General inflammation — cytokine modulation
Can You Use Both Together?
Many research protocols explore combining TB-4 and TB-500. The rationale:
- TB-4 provides the full signaling cascade including pathways unique to the complete peptide
- TB-500 provides enhanced distribution and the core repair signal with better tissue penetration
This combination attempts to get the best of both — complete biology from TB-4 plus superior tissue reach from TB-500.
Stacking with BPC-157
Both TB-4 and TB-500 are frequently combined with BPC-157, which works through entirely different mechanisms (nitric oxide, growth factors, gut-brain axis). See our BPC-157 vs TB-500 comparison for details.
Dosing Comparison
For research and educational discussion only.
| Protocol |
TB-4 |
TB-500 |
| Loading |
4–10 mg/week (divided) |
4–8 mg/week (divided) |
| Maintenance |
2–5 mg/week |
2–4 mg/week |
| Frequency |
2–3x per week |
2x per week |
| Duration |
4–12 weeks |
4–12 weeks |
| Reconstitution |
Bacteriostatic water, store 2–8°C |
Same |
Dosing is similar because TB-500's smaller size is offset by potentially lower per-molecule signaling breadth.
The Bottom Line
| If your research focus is... |
Consider |
| Cardiac repair / progenitor cells |
TB-4 (strongest evidence) |
| General healing on a budget |
TB-500 (better cost/distribution) |
| Maximum tissue penetration |
TB-500 (6x smaller molecule) |
| Broadest biological effect |
TB-4 (complete signaling cascade) |
| Stacking with BPC-157 |
Either (both are complementary) |
| Longest shelf stability |
TB-500 |
| Both combined |
TB-4 + TB-500 (full signal + broad reach) |
TB-4 is the more research-backed option with the complete mechanism. TB-500 is the practical, cost-effective option that delivers the core repair signal. Neither is wrong — the choice depends on research priorities and budget.
This article is for educational and research purposes only. It is not medical advice.